Skip to search formSkip to main contentSkip to account menu

Metastatic Disease Clinical Trial Setting

Known as: METASTATIC 
A clinical trial or treatment setting in which the therapy of interest is used to treat metastatic disease.
National Institutes of Health

Related topics

Related topics

2 relations
CDISC SDTM Treatment Setting TerminologyClinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2…
1000 Background: Pretreated HER2+ MBC lacks a defined standard of care, although T is commonly used. M has similar HER2 binding… 
Review
2017
Review
2017
The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
Highly Cited
2015
Highly Cited
2015
MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCND1
Metastasis is a leading cause of mortality for osteosarcoma patients. The molecular pathological mechanism remains to be… 
Highly Cited
2015
Highly Cited
2015
The Metastatic Spine Disease Multidisciplinary Working Group Algorithms.
The Metastatic Spine Disease Multidisciplinary Working Group consists of medical and radiation oncologists, surgeons, and… 
Highly Cited
2014
Highly Cited
2014
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Review
2014
Review
2014
Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer
Monitoring response to treatment is a key element in the management of breast cancer that involves several different viewpoints… 
Highly Cited
2014
Highly Cited
2014
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Highly Cited
2009
Highly Cited
2009
Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions
BackgroundHypoxia inducible factor-1 alpha (HIF-1α) protein is rapidly degraded under normoxic conditions. When oxygen tensions… 
Highly Cited
2005
Highly Cited
2005
CCI‐779 in metastatic melanoma
CCI‐779 is an analog of the immunosuppressive agent, rapamycin, that has demonstrated activity against melanoma in preclinical… 
Highly Cited
1991
Highly Cited
1991
Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil.
Undifferentiated nasopharyngeal carcinoma (UCNT) is known to be radiosensitive and chemosensitive, but the latter has never been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)